Health Care International - Medivation Announces Presentation Of Positive MDV3100 Clinical Data In Castration-Resistant Prostate Cancer Patients At 44th ASCO Annual Meeting
Medivation, Inc. (Nasdaq: MDVN) announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate speci
Comments